Condition

Opiate Dependence

ClinicalTrials.gov condition label

Clinical trials18

Recruiting0

Common interventions25

Lead sponsors shown10

Clinical trials

18 shown

Accelerated Intermittent Theta-Burst Stimulation for Opiate Use DisorderNCT03804619 · 2024-01-01

Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid DependenceNCT02602795 · 2015-12-01

Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release NaltrexoneNCT01882361 · 2013-06-01

Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in MalaysiaNCT01863251 · 2013-05-01

Project FIRST - Financial Incentives to Reduce Substance Use and Improve TreatmentNCT01376570 · 2012-06-01

Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in RussiaNCT01389167 · 2011-09-01

Behavioral Drug and HIV Risk Reduction Counseling With MMT in ChinaNCT01389180 · 2010-12-01

Linking Hospitalized Injection Drug Users to BuprenorphineNCT00987961 · 2009-09-01

Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk ReductionNCT00609089 · 2008-03-01

Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in MalaysiaNCT00539123 · 2007-09-01

Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in ChinaNCT00757744 · 2007-09-01

Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid DependenceNCT00548275 · 2006-07-01

Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent ParticipantsNCT00130819 · 2005-11-01

Integrating Buprenorphine Into HIV TreatmentNCT00241930 · 2005-09-01

The CORE Buprenorphine Project - An HIV Primary Care Program DemonstrationNCT00227357 · 2005-07-01

HIV Risk Reduction and Drug Abuse Treatment in IranNCT00398008 · 2004-10-01

Brief Introductory Therapy for Opioid DependenceNCT00406484 · 2004-09-01

HIV Risk Reduction and Drug Abuse Treatment in MalaysiaNCT00383045 · 2003-04-01

Common interventions

BDRCBEHAVIORAL2 Behavioral Drug and HIV Risk Reduction Counseling (BDRC)BEHAVIORAL2 Buprenorphine/SubutexDRUG2 Drug counselingBEHAVIORAL2 NaltrexoneDRUG2 Treatment as UsualBEHAVIORAL2 abstinence-contingent buprenorphine (ACB)BEHAVIORAL1 Abstinence-reinforcing contingency management interventionBEHAVIORAL1 Accelerated intermittent theta-burst stimulation (aiTBS)DEVICE1 Acceptance and Commitment TherapyBEHAVIORAL1 AtomoxetineDRUG1 Behavioral Drug and HIV Risk Reduction CounselingBEHAVIORAL1 Case management and referred substance abuse treatmentBEHAVIORAL1 Clinic-based substance abuse treatment with buprenorphineBEHAVIORAL1 CRAFT-TBEHAVIORAL1 Drug counselingPROCEDURE1 Educational CounselingBEHAVIORAL1 Enhanced Sexual Risk ManagementBEHAVIORAL1 Information Motivation Behavioral ModelBEHAVIORAL1 injectable naltrexoneDRUG1 Integrating drug treatment into HIV servicesBEHAVIORAL1 LinkageBEHAVIORAL1 Medical ManagementBEHAVIORAL1 Naltrexone (oral)DRUG1 Off-site - methadone or no agonistDRUG1

Leading sponsors

Yale University9 Albert Einstein College of Medicine1 Butler Hospital1 Johns Hopkins University1 Organization to Achieve Solutions in Substance Abuse (OASIS)1 Rhode Island Hospital1 Ruth M. Rothstein CORE Center1 Stanford University1 University of Cincinnati1 University of Pennsylvania1

Trial status mix

COMPLETED14

UNKNOWN2

WITHDRAWN2

Phase mix

PHASE28

PHASE35

NA4

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.